Conceptual and molecular docking study of newly developed antiepileptic drug cenobamate

In the past two decades, there has been sudden development in antiepileptic drugs (AEDs) for the adjunctive treatment of epilepsy. CNB is a leading-edge new generation tetrazole-derived carbamate for the treatment of focal-onset epileptic seizures where the mode of action is mediated by blocking voltage-gated sodium channels and interaction with the GABAergic system. The US FDA approved CNB with new hope for superior control over seizure, better safety, and tolerability profile compared to earlier AEDs.